Precision Medicine in Oncology®

Since the Warburg effect has been observed in the majority of cancer types, many studies have focused on developing therapies that target metabolic pathways.

Cancer cells must maintain a delicate balance to prevent catastrophic levels of DNA damage from triggering cell death, and their heavy reliance on the remaining normal DNA damage response components creates a therapeutically targetable Achilles’ heel.

Maurie Markman, MD, discusses how to address the important issue of survival following a cancer diagnosis.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.

Maurie Markman, MD discusses the importance of objective evidence when using a combination approach as opposed to a single-agent treatment.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT-mutated cancers, suggesting the validity of tailoring treatment to tumor genes.

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.